외상성 뇌손상 바이오마커 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 유형별, 샘플 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Traumatic Brain Injury Biomarkers Market Summary

The global traumatic brain injury biomarkers market size was estimated at USD 1.04 billion in 2024 and is projected to reach USD 4.73 billion by 2033, growing at a CAGR of 18.84% from 2025 to 2033. The market is facing significant growth driven by rising incidents of traumatic brain injuries, growing demand for rapid and point-of-care diagnostics, and a shift towards personalized medicine and telehealth.

Traumatic brain injury (TBI) remains a major global health concern, ranking among the leading causes of long-term disability and mortality. According to the Centers for Disease Control and Prevention, in 2024, 2.8 million people in America were diagnosed with brain injury every year, and more than 56,000 people died as a result of TBI. Although everyone is at risk of sustaining a traumatic brain injury (TBI), males are approximately 1.5 times more likely than females to experience a TBI and have a mortality rate that is three times higher.

Factors such as increasing road traffic accidents, sports-related injuries, falls among the elderly, and military combat injuries contribute significantly to this trend. Each year, traumatic brain injury (TBI) results in disability for six times more individuals than spinal cord injuries, multiple sclerosis, HIV/AIDS, and breast cancer combined. The pie chart below illustrates leading causes of TBI:

This surge in TBI cases fuels demand for reliable, early diagnostic tools like biomarkers that can aid in timely detection and treatment, ultimately driving market growth.

Individuals aged 65 and above are the most vulnerable to hospitalization and death caused by traumatic brain injury (TBI), with falls being the leading cause. Across all age groups, men experience higher rates of severe TBI compared to women, and they are not only more frequently hospitalized but also face nearly triple the risk of death from TBI.

Thus, there is a growing need for rapid, portable, and point-of-care diagnostic tools for TBI, particularly in pre-hospital environments such as accident scenes, sports fields, and military battlefields. Biomarker-based tests that provide quick and accurate results enable timely clinical decisions, improving patient outcomes and reducing healthcare costs.

Studies are being conducted to investigate whether biomarkers can be used in clinical trials to support the development of new treatments for traumatic brain injury (TBI). These biomarkers could improve the diagnosis and evaluation of TBI severity, facilitating the selection of suitable patients for participation in drug trials. One such study reported by the USFDA, conducted in September 2022, focused on identifying and validating diagnostic biomarkers that accurately detected traumatic brain injury (TBI) and assessed the severity to improve early diagnosis and patient management. The study successfully identified potential biomarkers that demonstrated a strong correlation with TBI presence and severity, laying the groundwork for improved diagnostic tools and enabling more precise patient selection in future clinical trials.

The increasing focus on personalized medicine is driving demand for biomarker-based diagnostics tailored to individual patient profiles and severity of injury. Biomarkers enable clinicians to customize treatment strategies, improving outcomes and reducing adverse effects. Innovations in biomarker identification tests are in development with a focus on personalized medicine.

For instance, in May 2024, bioMerieux received U.S. FDA 510(k) clearance for VIDAS TBI, a serum-based test designed to assist in evaluating patients with mild traumatic brain injury (mTBI), including concussions. This test assists in detecting patients who are unlikely to have acute intracranial lesions (ICL), which helps decrease the number of unnecessary head CT scans. VIDAS TBI also enables healthcare providers to make faster, better-informed decisions tailored to individual patient needs. Thus, inculcating such approaches promotes continuous monitoring and timely intervention, supporting market growth by integrating biomarker testing into personalized therapeutic approaches.

Global Traumatic Brain Injury Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global traumatic brain injury biomarkers market report based on type, sample type, application, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Protein Biomarkers
• Genetic Biomarkers
• Metabolomic Biomarkers
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Blood-based
• Cerebrospinal fluid (CSF)-based
• Urine-based
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnosis
• Prognosis
• Monitoring treatment response
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Sample Type
  • 1.2.3. Application
  • 1.2.4. End use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Sample type outlook
  • 2.2.3. Application outlook
  • 2.2.4. End use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Traumatic Brain Injury Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Traumatic Brain Injury Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Traumatic Brain Injury Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2024 & 2033
• 4.2. Segment Dashboard
• 4.3. Traumatic Brain Injury Biomarkers Market: Type Movement Analysis
• 4.4. Traumatic Brain Injury Biomarkers Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.5. Traumatic Brain Injury Biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Protein biomarkers
  • 4.6.1. Protein biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.7. Genetic biomarkers
  • 4.7.1. Genetic biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)
• 4.8. Metabolomic biomarkers
  • 4.8.1. Metabolomic biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Traumatic Brain Injury Biomarkers Market: Sample type Estimates & Trend Analysis

• 5.1. Sample type Market Share, 2024 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Traumatic Brain Injury Biomarkers Market by Sample type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Blood-based
  • 5.5.1. Blood-based Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.6. Cerebrospinal fluid (CSF)-based
  • 5.6.1. Cerebrospinal fluid (CSF)-based Market estimates and forecasts, 2021 to 2033 (USD Million)
• 5.7. Urine-based
  • 5.7.1. Urine-based Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Traumatic Brain Injury Biomarkers Market: Application Estimates & Trend Analysis

• 6.1. Application Market Share, 2024 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Traumatic Brain Injury Biomarkers Market by Application Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Diagnosis
  • 6.5.1. Diagnosis Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.6. Prognosis
  • 6.6.1. Prognosis Market estimates and forecasts, 2021 to 2033 (USD Million)
• 6.7. Monitoring treatment response
  • 6.7.1. Monitoring treatment response Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Traumatic Brain Injury Biomarkers Market: End use Estimates & Trend Analysis

• 7.1. End use Market Share, 2024 & 2033
• 7.2. Segment Dashboard
• 7.3. Global Traumatic Brain Injury Biomarkers Market by End use Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Hospitals & Clinics
  • 7.5.1. Hospitals & Clinics Market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.6. Diagnostic Laboratories
  • 7.6.1. Diagnostic Laboratories Market estimates and forecasts, 2021 to 2033 (USD Million)
• 7.7. Research Institutes
  • 7.7.1. Research Institutes Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Traumatic Brain Injury Biomarkers Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.5. North America
  • 8.5.1. North America: SWOT Analysis
  • 8.5.2. U.S.
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/Reimbursement
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/Reimbursement
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/Reimbursement
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe: SWOT Analysis
  • 8.6.2. UK
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/Reimbursement
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/Reimbursement
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/Reimbursement
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/Reimbursement
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/Reimbursement
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6.7. Norway
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/Reimbursement
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/Reimbursement
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6.9. Denmark
    • 8.6.9.1. Key country dynamics
    • 8.6.9.2. Regulatory framework/Reimbursement
    • 8.6.9.3. Competitive scenario
    • 8.6.9.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific: SWOT Analysis
  • 8.7.2. Japan
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/Reimbursement
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/Reimbursement
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/Reimbursement
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7.5. Australia
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/Reimbursement
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7.6. South Korea
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/Reimbursement
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/Reimbursement
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America: SWOT Analysis
  • 8.8.2. Brazil
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/Reimbursement
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/Reimbursement
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
• 8.9. MEA
  • 8.9.1. MEA: SWOT Analysis
  • 8.9.2. South Africa
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/Reimbursement
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/Reimbursement
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/Reimbursement
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key country dynamics
    • 8.9.5.2. Regulatory framework
    • 8.9.5.3. Competitive scenario
    • 8.9.5.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2024
    • 9.3.3.1. Quanterix.
      • 9.3.3.1.1. Company overview
      • 9.3.3.1.2. Financial performance
      • 9.3.3.1.3. Services benchmarking
      • 9.3.3.1.4. Strategic initiatives
    • 9.3.3.2. Banyan Biomarkers, Inc.
      • 9.3.3.2.1. Company overview
      • 9.3.3.2.2. Financial performance
      • 9.3.3.2.3. Services benchmarking
      • 9.3.3.2.4. Strategic initiatives
    • 9.3.3.3. Abbott
      • 9.3.3.3.1. Company overview
      • 9.3.3.3.2. Financial performance
      • 9.3.3.3.3. Services benchmarking
      • 9.3.3.3.4. Strategic initiatives
    • 9.3.3.4. Siemens Healthineers AG
      • 9.3.3.4.1. Company overview
      • 9.3.3.4.2. Financial performance
      • 9.3.3.4.3. Services benchmarking
      • 9.3.3.4.4. Strategic initiatives
    • 9.3.3.5. GE Healthcare.
      • 9.3.3.5.1. Company overview
      • 9.3.3.5.2. Financial performance
      • 9.3.3.5.3. Services benchmarking
      • 9.3.3.5.4. Strategic initiatives
    • 9.3.3.6. Koninklijke Philips N.V.
      • 9.3.3.6.1. Company overview
      • 9.3.3.6.2. Financial performance
      • 9.3.3.6.3. Services benchmarking
      • 9.3.3.6.4. Strategic initiatives
    • 9.3.3.7. Fujirebio
      • 9.3.3.7.1. Company overview
      • 9.3.3.7.2. Financial performance
      • 9.3.3.7.3. Services benchmarking
      • 9.3.3.7.4. Strategic initiatives
    • 9.3.3.8. Thermo Fisher Scientific Inc.
      • 9.3.3.8.1. Company overview
      • 9.3.3.8.2. Financial performance
      • 9.3.3.8.3. Services benchmarking
      • 9.3.3.8.4. Strategic initiatives
    • 9.3.3.9. Randox Laboratories Ltd.
      • 9.3.3.9.1. Company overview
      • 9.3.3.9.2. Financial performance
      • 9.3.3.9.3. Services benchmarking
      • 9.3.3.9.4. Strategic initiatives
    • 9.3.3.10. Immunarray.
      • 9.3.3.10.1. Company overview
      • 9.3.3.10.2. Financial performance
      • 9.3.3.10.3. Services benchmarking
      • 9.3.3.10.4. Strategic initiatives
    • 9.3.3.11. Oculogica
      • 9.3.3.11.1. Company overview
      • 9.3.3.11.2. Financial performance
      • 9.3.3.11.3. Services benchmarking
      • 9.3.3.11.4. Strategic initiatives
    • 9.3.3.12. NeuroTrauma Sciences, LLC
      • 9.3.3.12.1. Company overview
      • 9.3.3.12.2. Financial performance
      • 9.3.3.12.3. Services benchmarking
      • 9.3.3.12.4. Strategic initiatives
    • 9.3.3.13. BRAINBox Solutions, Inc.
      • 9.3.3.13.1. Company overview
      • 9.3.3.13.2. Financial performance
      • 9.3.3.13.3. Services benchmarking
      • 9.3.3.13.4. Strategic initiatives
    • 9.3.3.14. BioMerieux
      • 9.3.3.14.1. Company overview
      • 9.3.3.14.2. Financial performance
      • 9.3.3.14.3. Services benchmarking
      • 9.3.3.14.4. Strategic initiatives
    • 9.3.3.15. Myriad Genetics, Inc.
      • 9.3.3.15.1. Company overview
      • 9.3.3.15.2. Financial performance
      • 9.3.3.15.3. Services benchmarking
      • 9.3.3.15.4. Strategic initiatives
    • 9.3.3.16. QIAGEN N.V.
      • 9.3.3.16.1. Company overview
      • 9.3.3.16.2. Financial performance
      • 9.3.3.16.3. Services benchmarking
      • 9.3.3.16.4. Strategic initiatives
    • 9.3.3.17. F. Hoffmann-La Roche Ltd
      • 9.3.3.17.1. Company overview
      • 9.3.3.17.2. Financial performance
      • 9.3.3.17.3. Services benchmarking
      • 9.3.3.17.4. Strategic initiatives
    • 9.3.3.18. Abcam Limited
      • 9.3.3.18.1. Company overview
      • 9.3.3.18.2. Financial performance
      • 9.3.3.18.3. Services benchmarking
      • 9.3.3.18.4. Strategic initiatives